Evaluating inflammatory joint disease: How and when can autoantibodies help?

Joint Bone Spine

Volumn 70, Issue 6, 2003, Pages 433-447

  Meyer, Olivier ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Anticitrullinated protein antibodies; Antineutrophil cytoplasmic antibodies; Antinuclear antibodies; Inflammatory joint disease; Rheumatoid factors

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTIPERINUCLEAR FACTOR; AUTOANTIBODY; BIOLOGICAL MARKER; CALPASTATIN; CELL NUCLEUS ANTIGEN; CENTROMERE ANTIBODY; CITRULLINE; DNA ANTIBODY; DNA TOPOISOMERASE; DOUBLE STRANDED DNA; ENZYME ANTIBODY; FILAGGRIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KERATIN ANTIBODY; LA ANTIBODY; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NUCLEOLAR ANTIBODY; NUCLEOSOME ANTIBODY; PEPTIDE ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN; RIBOSOME ANTIBODY; RO ANTIBODY; SM ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; AGED; ANTIBODY DETECTION; CASE REPORT; CLINICAL FEATURE; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HEP 2 CELL; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE; INFLAMMATORY DISEASE; INFLAMMATORY JOINT DISEASE; LABORATORY TEST; LUPUS ERYTHEMATOSUS; MALE; MIXED CONNECTIVE TISSUE DISEASE; PATIENT CODING; POLYMYOSITIS; RADIOIMMUNOASSAY; RHEUMATOID ARTHRITIS; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SJOEGREN SYNDROME; SMALL VESSEL VASCULITIS; STATISTICAL ANALYSIS; SYMPTOM; SYSTEMIC SCLEROSIS; TECHNIQUE; WEGENER GRANULOMATOSIS;

EID: 0347363688     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2003.07.004     Document Type: Conference Paper

References (96)

1. American College of Rheumatology ad hoc committee on immunologic testing guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: an introduction. Arthritis Rheum [Arthritis Care Res] 2002;47:329-33.
2. Vittecoq O, de Bandt M, Meyer O, Hachulla E, le Loët X, les membres du CRI. Les facteurs rhumatoïdes sont-ils utiles au diagnostic nosologique d'un rhumatisme inflammatoire évoluant depuis moins de 12 mois en l'absence de signes cliniques d'orientation? Rev Rhum 2002;69:135-8.
3. Saraux A, Berthelot JM, Chales G, Le Henaff C, Mary JY, Thorel JB, et al. Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum 2002;47:155-65.
4. Berthelot JM, Wendling D, Combe B, Le Loët X, Saraux A, pour le CRI. Performances des critères 1987 de polyarthrite rhumatoïde de l'American College of Rheumatology dans le contexte des arthrites débutantes: étude de la littérature. Rev Rhum [ed Fr] 2002;69:128-34.
5. Meyer O. Les auto-anticorps devant un rhumatisme inflammatoire débutant. In: Blotman F, Combes B, Leroux JL, Sany J, editors. Journées montpelliéraine de Rhumatologie. Montpellier: Sauramps medical ed; 2001. p. 51-60.
6. Schellekens GA, Visser H, de Jong BAW, van den Hoogen FHJ, Hazes JMW, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
7. Goldbach-Mansdky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-43.
8. Jansen AMIE, van der Horst-Bruinsma IE, van Schaardenburg D, van de Stadt RJ, de Koning MHMT, Dijkmans BAC. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis inpatients with early arthritis. J Rheumatol 2002;29:2074-6.
9. Harrison BJ, Symmons DPM, Barrett EM, Silman AJ. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. J Rheumatol 1998;25:2324-30.
10. Saraux A, Berthelot JM, Chalès G, Le Henaff C, Thorel JB, Hoang S, et al. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients 2 years later. Arthritis Rheum 2001;44:2485-91.
11. Cordonnier C, Meyer O, Palazzo E, De Bandt M, Elias A, Nicaise P. Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol 1996;35:620-4.
12. Von Essen R, Kurki P, Isomaki H, Okubo S, Kautiainen H, Aho K. Prospect for an additional laboratory criterion for rheumatoid arthritis. Scand J Rheumatol 1993;22:267-72.
13. Schmerling RH, Delbanco TL. How useful is the rheumatoid factor? An analysis of sensitivity, specificity and predictive value. Arch Intern Med 1992;152:2417-20.
14. Saraux A, Valls I, Voisin V, Koreichi A, Baron D, Youinou P, et al. How useful are tests for rheumatoid factors, antiperinuclear factors, antikeratin antibody, and the HLA DR4 antigen for the diagnosis of rheumatoid arthritis? Rev Rhum 1995;62:16-20.
15. Shmerling RH, Delbanco TL. The rheumatoid factor: an analysis of clinical utility. Am J Med 1991;91:528-34.
16. Vittecoq O, Jouen-Beades F, Krzanowska K, Bichon-Tauvel I, Ménard JF, Daragon A, et al. Les facteurs rhumatoïdes, les anticorps antifilaggrine et la faible production in vitro d'interleukine 2 et d'interféron-gamma sont des marqueurs immunologiques utiles au diagnostic précoce de la polyarthrite rhumatoïde dans une population de recrutement libéral. Etude préliminaire. Rev Rhum 2001;68:239-49.
17. Wolfe F, Cathey MA, Roberts FK. The latex test revisited. Rheumatoid factor testing in 8287 rheumatic disease patients. Arthritis Rheum 1991;34:951-60.
18. Jonsson T, Steisson K, Jonsson H, Geirsson AJ, Thorsteinsson J, Valdimarsson H. Combined elevation of IgM and IgA rheumatoid factor has high diagnostic specificity for rheumatoid arthritis. Rheumatol Int 1998;18:119-22.
19. Berthelot JM, Maugars Y, Castagne A, Audrain M, Prost A. Antiperinuclear factors are present in polyarthritis before ACR criteria for rheumatoid arthritis are fulfilled. Ann Rheum Dis 1997;56:123-5.
20. Swedler W, Wallman J, Froelich CJ, Teodorescu M. Routine measurement of IgM, IgG and IgA rheumatoid factors: high sensitivity, specificity and predictive value for rheumatoid arthritis. J Rheumatol 1997;24:1037-44.
21. Visser H, Gelinck LBS, Kampfraath AH, Breedveld FC, Hazes JMW. Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 1996;55:157-61.
22. Berthelot JM, Garnier P, Glémarec J, Flipo RM. Valeur des anticorps anti-périnucléaires au 1:100 pour le diagnostic de polyarthrite rhumatoïde. Etude de 600 patients et méta-analyse de la littérature. Rev Rhum 1998;65:9-15.
23. Hoet RM, Van Venrooij WJ. The antiperinuclear factor (APF) and antikeratin antibodies (AKA) in rheumatoid arthritis. In: Smolen JS, Kalden JR, Maini RN, editors. Rheumatoid arthritis. Berlin: Heidelberg: Springer; 1992. p. 299-318.
24. Aho K, Von Essen R, Kurki P, Palosuo T, Heliovaara M. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol 1993;20:1278-81.
25. Alnigenis NNY, Warikoo S, Barland P. Antiperinuclear factor and antikeratin antibody: diagnostic use in a clinical laboratory setting. J Rheumatol 2000;27:2056-7.
26. Vincent C, de Keyser F, Masson-Bessière C, Sebbag M, Veys EM, Serre G. Anti-perinuclear factor compared with the so called "antik-ratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritis. Ann Rheum Dis 1999;58:42-8.
27. Van Jaarsveld CHM, ter Borg EJ, Jacobs JWG, Schellekens GA, Gmeling-Meyling FH, van Booma-Frankfort C, et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 1999;17:689-97.
28. Forslind K, Vincent C, Serre G, Svensson B. Antifilaggrin autoantibodies in early rheumatoid arthritis. Scand J Rheumatol 2000;29:320-2.
29. Aho K, Palosuo T, Lukka M, Kurki P, Isomaki H, Kautiainen H, et al. Antifilaggrin antibodies in recent-onset arthritis. Scand J Rheumatol 1999;28:113-6.
30. Le Goff P, Youinou P, Jouquan J. Etude de la précocité d'apparition des anticorps antikératine. Rev Rhum 1986;53:699-700.
31. Meyer O, Fabregas D, Cyna L, Ryckewaert A. Les anticorps antikératine. Un marqueur des polyarthrites rhumatoïdes évolutives. Rev Rhum 1986;53:601-5.
32. Kroot EJJA, de Jong BAW, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Holf M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
33. Paimela L, Palosuo T, Aho K, Lukka M, Kurki P, Leirisalo-Repo M, et al. Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis. Ann Rheum Dis 2001;60:32-5.
34. Union A, Meheus L, Humbel RL, Conrad K, Steiner G, Moereels H, et al. Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum 2002;46:1185-95.
35. Vincent C, Nogueira L, Sebbag M, Chapuy-Regaud S, Arnaud M, Letourneur O, et al. Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay. A highly effective test for the diagnosis of rheumatoid arthritis. Arthritis Rheum 2002;46:2051-8.
36. Serre G. Autoanticorps antifilaggrine/antifibrine déiminée. Outre leur intérêt diagnostique et pronostique, les autoanticorps antifilaggrine/antifibrine déiminée (AFA) sont probablement impliqués dans la physiopathogénie rhumatoïde. Rev Rhum 2001;68:201-3.
37. Vincent C, Simon M, Sebbag M, Girbal-Neuhauser E, Durieux JJ, Cantagrel A, et al. Immunoblotting detection of autoantibodies to human epidermis filaggrin: a new diagnostic test for rheumatoid arthritis. J Rheumatol 1998;25:838-46.
38. Palosuo T, Lukka M, Alenius H, Kalkkinen N, Aho K, Kurki P, et al. Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay. Int Arch Allergy Immunol 1998;115:294-302.
39. Schellekens GA, de Jong BAW, Van den Hoogen FHJ, Van de Putte LBA. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.
40. Menard HA, Lapointe E, Rochd MD, Zhou ZJ. Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res 2000;2:429-32.
41. Hayem G, Chazerain P, Combe B, Elias A, Haim T, Nicaise P, et al. Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol 1999;26:7-13.
42. Hueber W, Hassfeld W, Smolen JS, Steiner G. Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatol 1999;38:155-9.
43. Desprès N, Boire G, Lopez-Longo FJ, Ménard HA. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 1994;21:1027-33.
44. Hassfeld W, Steiner G, Hartmuth K, Kolarz G, Scherak O, Graninger W, et al. Demonstration of a new antinuclear antibody (anti-RA 33) that is highly specific for rheumatoid arthritis. Arthritis Rheum 1989;32:1515-20.
45. Hassfeld W, Steiner G, Graninger W, Witzmann G, Schweitzer H, Smolen JS. Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol 1993;32:199-203.
46. Després N, Talbot G, Plouffe B, Boire G, Ménard A. Detection and expression of a cDNA clone that encodes a polypeptide containing two inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera. J Clin Invest 1995;95:1891-6.
47. Mimori T, Suganuma K, Tanami Y, Nojima T, Matsumura M, Fujii T, et al. Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases. Proc Natl Acad Sci USA 1995;92:7267-71.
48. Homburger HA. Cascade testing for autoantibodies in connective tissue diseases. Mayo Clin Proc 1995;70:183-4.
49. Tan EM, Feltkamp TEW, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997;40:1601-11.
50. Craig WY, Ledue TB, Johnson AM, Ritchie RF. The distribution of antinuclear antibody titers in "normal" children and adults. J Rheumatol 1999;26:914-9.
51. Emlen W, O'Neill L. Clinical significance of antinuclear antibodies. Comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum 1997;40:1612-8.
52. Kavanaugh AF, Solomon DH, American College of Rheumatology ad hoc committee on immunologic testing guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum [Arthritis Care Res] 2002;47:546-55.
53. Solomon DH, Kavanaugh AJ, Schur PH, American College of Rheumatology ad hoc committee on immunologic testing guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum [Arthritis Care Res] 2002;47:434-44.
54. Smeenk RJT. Detection of antibodies to dsDNA: current insights into its relevance. Clin Exp Rheumatol 2002;20:294-300.
55. Amoura Z, Koutouzov S, Chabre H, Cacoub P, Amoura I, Musset L, et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases. Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000;43:76-84.
56. Chabre H, Amoura Z, Piette JC, Godeau P, Bach JF, Koutouzov S. Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1995;38:1485-91.
57. Ben Hadj Hmida Y, Schmit P, Gilson G, Humbel RL. Failure to detect antinucleosome antibodies in scleroderma: comment on the article by Amoura et al. Arthritis Rheum 2002;46:280-2.
58. Bruns A, Bläß S, Hausdorf G, Burmester GR, Hiepe F. Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum 2000;43:2307-15.
59. Goetz J, Humbel RL, Monier JC, Cohen J, André C, Bacquery A, et al. Diagnostic value of nucleosome specific antibodies in recent active non treated SLE. Arthritis Rheum 2000;43:S379 (abstract 1878).
60. Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer-Green G. The evolution of Raynaud's phenomenon: a long-term prospective study. J Rheumatol 1995;22:2226-32.
61. Reveille JD, Solomon DH. American College of Rheumatology ad hoc committee on immunologic testing guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70 and nucleolar antibodies. Arthritis Rheum [Arthritis Care Res] 2003;49:399-412.
62. Tubach F, Hayem G, Elias A, Nicaise P, Haït T, Kahn MF, et al. Les anticorps anticentromère en pratique rhumatologique ne sont pas toujours associés à une sclérodermie. Rev Rhum 1997;64:425-30.
63. Bodolay E, Csiki Z, Szekanecs Z, Ben T, Kiss E, Zeher M, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 2003;21:313-20.
64. Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 1999;17:615-20.
65. Danieli MG, Fraticelli P, Franceschini F, Cattaneo R, Farsi A, Passaleva A, et al. Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases. Clin Exp Rheumatol 1999;17:585-91.
66. Cavazzana I, Franceschini F, Belfiore N, Quinzanini M, Caporali R, Calzavara-Pinton P, et al. Undifferentiated connective tissue disease with antibodies to Ro/SSA: clinical features and follow-up of 148 patients. Clin Exp Rheumatol 2001;19:403-9.
67. Meilof JF, Bantjes I, De Jong J, van Dam AP, Smeenk RJT. The detection of anti-Ro/SSA and anti-La/SSB antibodies. A comparison of counterimmunoelectrophoresis with immunoblot, ELISA, and RNA-precipitation assays. J Immunol Methods 1990;133:215-26.
68. Morozzi G, Bellisai F, Simpatico A, Pucci G, Bacarelli MR, Campanella V, et al. Comparison of different methods for the detection of anti-Ro/SSA antibodies in connective tissue disease. Clin Exp Rheumatol 2000;18:729-31.
69. Manoussakis MN, Kistis KG, Liu X, Aidinis V, Guialis A, Moutsopoulos HM. Detection of anti-Ro (SSA) antibodies in autoimmune diseases: comparison of five methods. Br J Rheumatol 1993;32:449-55.
70. Tan EM, Smolen JS, mcDougal JS, Butcher BT, Conn D, Dawkins R, et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity and specificity. Arthritis Rheum 1999;42:455-64.
71. Pourmand N, Blomberg S, Rönnblom L, Karlsson-Parra A, Pettersson I, Wahren-Herlenius M. Ro 52 kDa autoantibodies are detected in a subset of ANA-negative sera. Scand J Rheumatol 2000;29:116-23.
72. Peene I, Meheus L, Veys EM, de Keyser F. Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Ann Rheum Dis 2002;61:1090-4.
73. Srivastava M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 2003;139:45-9.
74. Brucato A, Franceschini F, Gasparini M, de Juli E, Ferraro G, Quinzanini M, et al. Isolated congenital complete heart block: long-term outcome of mothers, maternal antibody specificity and immunogenetic background. J Rheumatol 1995;22:533-40.
75. Julkunen H, Kurki P, Kaaja R, Heikkilä R, Immonen I, Chan EKL, et al. Isolated congenital heart block. Long-term outcome of mothers and characterization of the immune response to SS-A/Ro and to SS-B/La. Arthritis Rheum 1993;36:1588-98.
76. Peene I, Meheus L, de Keyser S, Humbel R, Veys EM, de Keyser F. Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis 2002;61:929-33.
77. Ben-Chetrit E, Fox RI, Tan EM. Dissociation of immune responses to the SSA (Ro) 52 and 60 kDa polypeptides in systemic lupus erythematosus and Sjögren's syndrome. Arthritis Rheum 1990;33:349-55.
78. Rutjes SA, Vree Egberts WTM, Jongen P, van den Hoogen F, Pruijn GJM, van Venrooij WJ. Anti-Ro 52 antibodies frequently co-occur with anti-J01 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997;109:32-40.
79. Simmons-O'Brien E, Chen S, Watson R, Antoni C, Petri M, Hochberg M, et al. One hundred anti-Ro (SSA) antibody positive patients: a 10-year follow-up. Medicine 1995;74:109-30.
80. Sibilia J, Goetz J, Berthel C, Koegler A, Maloisel F, Javier RM. Signification clinique et biologique des anticorps anti-Ro/SSA. Etude et suivi d'un groupe de 127 patients avec anticorps anti-Ro/SSA. In: Abuaf N, Pierron D, Rouquette AM, editors. Anticorps anti-SSA/Ro Méthode de dépistage. Valeur diagnostique, BMD; 1996. p. 91-112.
81. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
82. Venables PJW, Shattles W, Pease CT, Ellis JE, Charles PJ, Maini RN. Anti-La (SSB): a diagnostic criterion for Sjögren's syndrome? Clin Exp Rheumatol 1989;7:181-4.
83. Johanet C, André C, Sibilia J, Baquey A, Oksman F, San Marco M, et al. Signification clinique des anticorps antiribosomes. Rev Méd Interne 2000;21:510-6.
84. Watts RA, Scott DGI. Epidemiology of the vasculitides. Curr Opin Rheumatol 2003;15:11-6.
85. Alcalay M, Azais I, Pallier B, Touchard G, Patte F, Brugier JC, et al. Les manifestations articulaires de la maladie de Wegener. A propos de 13 observations. Rev Rhum 1990;57:845-53.
86. Rao JK, Weinberg M, Oddone EZ, Allen NB, Landsman P, Feussner JR. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med 1995;123:925-32.
87. Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, et al. Diagnostic value of standardized assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int 1998;53:743-53.
88. Stone JH, Talor M, Stebbing J, Uhlfelder ML, Rose NR, Carson KA, et al. Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions. Arthritis Rheum [Arthritis Care Res] 2000;13:424-34.
89. Choi HK, Liu S, Merkel PA, Colditz GA, Niles JL. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. J Rheumatol 2001;28:1584-90.
90. Hachulla E, De Bandt M, Dubucquoi S, Vittecoq O, Le Loët X, Meyer O, et al. Intérêt du dosage des anticorps antinucléaires, des anticorps antiphospholipides et des anticorps anticytoplasme des neutrophiles dans le diagnostic nosologique des rhumatismes inflammatoires chroniques débutants sans signe clinique d'orientation. Rev Rhum [Ed Fr] 2002;69:139-46.
91. McLaren JS, Stimson RH, McRorie ER, Coia JE, Luqmani RA. The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. Q J Med 2001;94:615-21.
92. Rao JK, Allen NB, Freussner JR, Weinberger M. A prospective study of antineutrophil cytoplasmic antibody (c-ANCA) and clinical criteria in diagnosing Wegener's granulomatosis. Lancet 1995;346:926-31.
93. Piette JC, Wechsler B, Frances C, Papo T, Godeau P. Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol 1993;20:1802-4.
94. Weber M, Hayem G, De Bandt M, Seifert B, Palazzo E, Roux E, et al. Classification of an intermediate group of patients with antiphospholipid syndrome and lupus-like disease: primary or secondary antiphospholipid syndrome? J Rheumatol 1999;26:2131-6.
95. Meyer O, Nicaise P, Moreau S, de Bandt M, Palazzo E, Hayem G, et al. Antibodies to cardiolipin and beta 2 glycoprotein I in patients with polymyalgia rheumatica and giant cell arteritis. Rev Rhum [Engl Ed] 1996;63:241-7.
96. Min DJ, Kim SJ, Park SH, Seo YI, Kang HJ, Kim WU, et al. Anti-nucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody. Clin Exp Rheumatol 2002;20:13-8.